Dexcom Archives - Page 12 of 14 - Medical Design Sourcing

Lilly partners with four companies on insulin pen tech

Eli Lilly (NYSE:LLY) today announced deals with four companies whose diabetes management tech will work with on Lilly’s latest insulin pen.

The Tempo Pen is a modified version of Lilly’s existing prefilled, disposable insulin pen to which the Tempo Smart Button — in late-stage development – attaches. Through these new agreements, the Tempo Smart Button will pair with software and/or medical devices offered by Dexcom (NSDQ:DXCM), Glooko, myDiabby Healthcare (Bordeaux, France) and Roche, with its mySugr app, to facilitate the integration of personalized data and actionable insights.

Get the full story on our sister site, Drug Delivery Business News.

MedTech 100 roundup: Return to normal following recent spike

After back-to-back all-time best performances, the medtech industry had a slight regression over the course of the last week.

MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — had been continuously ticking up since the beginning of April, with its mark of 112.25 on April 16 representing an all-time best, topping the previous high of 110.96 set on Feb. 15.

Just one week later, the index topped itself again, reaching 114.58 to end the week on April 23, marking an increase of 2.1% from the previous week. However, things have settled down and the industry responded in kind, dipping -1.6% to 112.7 to end last week (April 30).

In spite of the slight decrease over the past week, the industry continues to reflect a bounceback from the struggles brought on by the COVID-19 pandemic.

Overall, has produced a 22.1% rise from the pre-pandemic high of 92.32 (set on Feb. 19, 2020), plus an 81.4% increase from…

Dexcom dips after hours despite Street-beating Q1, raised guidance

Dexcom (NSDQ:DXCM) shares took a hit after hours today despite first-quarter results that beat the consensus forecast.

DXCM shares were down -5.2% at $400 per share after hours. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was down -0.8%.

Get the full story at our sister site, Drug Delivery Business News.

Welldoc, Dexcom expand diabetes management tech partnership

Welldoc announced today that it will offer its BlueStar digital health solution with Dexcom’s G6 CGM system as a single platform.

Columbia, Md.-based Welldoc’s FDA-cleared BlueStar system offers guidance to individuals through the self-management of diabetes, while Dexcom’s G6 continuous glucose monitoring (CGM) system measures glucose levels just beneath the skin’s surface and wirelessly transmits data every five minutes.

Get the full story at our sister site, Drug Delivery Business News.

MedTech 100 roundup: Slight rise for the industry

While medtech’s performance still isn’t mirroring the beginning of 2021, the industry is showing signs of life with a small improvement last week.

The year’s strong start, during which MassDevice‘s MedTech 100 index notched an all-time best of 110.96 points (Feb. 15) came to an end later that month and carried over into March, with the index hitting its lowest recent point on March 8 (102.16), marking a fall at a level not seen since October.

Even after a slight rise earlier this month, the index struggled again two weeks ago with another small dip. However, after coming in at 104.05 on March 19, the index got a slight boost over the past week, finishing at 104.87 on March 26, representing a 0.8% rise.

Despite the up-and-down nature of the past couple of months, the index represents a much better situation for the industry compared to this time a year ago when the COVID-19 pandemic was in full swing. The index is up 13.6% from its pre-p…

How 5G could affect medtech

The latest standard of broadband technology continues to make waves in 2021. But what about medtech?

Cellphone using 5G

Cellphone using 5G (Imagy by Frederik Lipfert on Unsplash)

Wireless tech companies such as Qualcomm are predicting download speeds as high as 10 gigabits per second as next-generation 5G cellular networks roll out worldwide.

The open question in medtech is how quickly companies will take advantage of the super-speedy connectivity for their own products.

“5G is about bringing more capacity and speed to the pipes,” said Don Jones, a member of the advisory council at BrightInsight and a veteran of the digital healthcare space. Jones spent more than 11 years building Qualcomm’s healthcare group.

“What you have to analyze is, ‘Can healthcare take advantage of what essentially amounts to these bigger pipes?’ Because more data can be shoved through them with m…

Dexcom promotes Jereme Sylvain to CFO

Dexcom (NASDAQ: DXCM) announced today that it has promoted Jereme Sylvain to become a new EVP and CFO at the continuous glucose monitoring company.

Sylvain — who joined Dexcom in 2018 and was most recently SVP of finance and chief accounting officer — will report to COO Quentin Blackford.

Previously, Blackford had been serving as both COO and CFO of the San Diego–based company.

Get the full story on our sister site Drug Delivery Business News.

DTW Podcast: Insulet CEO Petrovic sees abundance of CGM opportunities

Insulet CEO Shacey Petrovic shares vision for OmniPod insulin delivery.

Medtech start ups developing continuous glucose monitors have caught the eye of at least one potential – and powerful – partner – Insulet Corp.

In an interview with the DeviceTalks Weekly Podcast, CEO Shacey Petrovic said the maker of the OmniPod insulin-delivery device sees partnering with other companies as the likely path to creating a single device capable of reading glucose levels and delivering insulin. Insulet last year announced partnerships with DexCom and Abbott.

“There are some really interesting technologies on the horizon,” Petrovic said. “There might be 40 early-stage CGMs in development so we’ll see how the market plays out. But we couldn’t be more delighted with our partnerships with Abbott and Dexcom.”

The partnerships give Insulet access to technology that’s able to measure glucose levels in…

DTW Podcast: CEO Petrovic explains how Insulet is switching people to `Pods

Insulet CEO Shacey Petrovic says she didn’t jump immediately at the chance to join the company.

In an interview with the DeviceTalks Weekly Podcast, Petrovic, who was serving as CEO of a women’s health company when CEO-Patrick Sullivan, her former boss at Cytyc, called her with an offer to serve as Insulet’s chief commercial officer

“I said, `Well, Pat, I’m a CEO now, you know, didn’t you hear?,” she joked.

A chief commercial officer role might be seen as a backward step from CEO, but Sullivan framed the question differently. He told Petrovic that he came out of retirement to take the CEO role and didn’t want to a long stint as CEO. “He said, `This could be your opportunity to eventually run a public company. If it goes well, I need a successor, the technology is remarkable, and together we can fix this problem.’”

A path the CEO role at a publicly traded company was certainly appealing. But Petrovic had more personal reason for the jo…

How CGM tech has advanced in the 21st century

The rapid evolution of the continuous glucose monitor (CGM) has brought flexibility and convenience to diabetes control.

Continuous glucose monitors (CGMs) have transformed how many people with diabetes manage blood sugar, but attempts to monitor blood glucose have a long history.

Efforts to manage glucose kicked off in earnest when researchers began measuring glucose in urine in the mid-1800s. Scientists’ ability to do so steadily improved over the years, but urine glucose testing wasn’t commercialized until 1908, establishing a foundation for diabetes care.

Elkhart, Ind.–based Ames Company refined the process in 1945 with the introduction of Clinitest reagent tablets, which are still commercially available, albeit from Bayer. The company would introduce the first blood glucose test strip in 1965. The Dextrostix-branded strips were intended for use in doctors’ offices.

In the 1970s, Ames developed a device known as the Ames Reflectance Meter to m…

How CGM tech has advanced in the 21st century

The rapid evolution of the continuous glucose monitor (CGM) has brought flexibility and convenience to diabetes control.

Continuous glucose monitors (CGMs) have transformed how many people with diabetes manage blood sugar, but attempts to monitor blood glucose have a long history.

Efforts to manage glucose kicked off in earnest when researchers began measuring glucose in urine in the mid-1800s. Scientists’ ability to do so steadily improved over the years, but urine glucose testing wasn’t commercialized until 1908, establishing a foundation for diabetes care.

Elkhart, Ind.–based Ames Company refined the process in 1945 with the introduction of Clinitest reagent tablets, which are still commercially available, albeit from Bayer. The company would introduce the first blood glucose test strip in 1965. The Dextrostix-branded strips were intended for use in doctors’ offices.

In the 1970s, Ames developed a device known as the Ames Reflectance Meter to m…

MedTech 100 roundup: Rise to new heights continues

The medtech industry hit another high as 2021 continues to bring strong performances out of some of the biggest companies around.

MassDevice‘s MedTech 100 index ended the week (Feb. 12) at 110.63 points, marking a 2.2% rise from the 108.23-point mark set at the end of the previous week (Feb. 5).

The final mark for the week sets an all-time best for the index, which had previously reached 106.81 points on Jan. 8, then 107.4 points on Jan. 20 before besting itself again with last week’s finish. The rise has been considerably impressive given that the index had never reached even the 100-point mark before November 2020.

Medtech’s latest rise means the index has risen 19.8% from the pre-COVID-19 pandemic high of 92.32, set on Feb. 19, 2020. Additionally, the industry has very much rebounded from its lowest place, a 62.13-point mark at the start of the pandemic on March 23, 2020. Since that point, the industry has jumped 78.1%.

Medtech’s performa…